Market Intelligence

Cigna’s Evernorth has announced plans to make a Humira biosimilar available for $0 out-of-pocket for Accredo patients from June, adding to momentum for adalimumab rivals from previous policy changes made by CVS in recent weeks. Meanwhile, AbbVie has offered the latest on how competition to its once top-selling brand is ramping up.

After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.

 The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.

Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.

Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.

A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.

As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.

A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.

As a number of major brands face generic and biosimilar competition, the loss-of-exclusivity impact across the leading 10 developed markets will approach $200bn over the next five years, according to a fresh medicines spending report running to 2028.

Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.

In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.

Organon CEO Kevin Ali provided a detailed overview of the firm’s biosimilars strategy at the J.P. Morgan Healthcare Conference last week, looking ahead to competition on Opdivo and Keytruda in 2028; highlighting nearer-term launches of denosumab and pertuzumab; and providing a breakdown of the firm’s experiences in the competitive US adalimumab market.

One of the sharpest UK generic price increases seen for years occurred in December, with riluzole 50mg tablets suddenly becoming more than 20 times more expensive than in the previous month, amid shortages of the motor neurone diseases treatment.

Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.